Use of Antipsychotic Drugs During Pregnancy

被引:3
作者
Betcher H.K. [1 ,2 ]
Montiel C. [1 ]
Clark C.T. [1 ,3 ]
机构
[1] Department of Psychiatry, Northwestern University Feinberg School of Medicine, 676 N. St. Clair St. Ste 1000, Chicago, 60611, IL
[2] Mayo Clinic, Rochester, MN
[3] Department of Obstetrics and Gynecology, Northwestern Feinberg School of Medicine, Chicago, IL
关键词
Antipsychotic; Breastfeeding; Lactation; Neuroleptic; Pregnancy;
D O I
10.1007/s40501-019-0165-5
中图分类号
学科分类号
摘要
Purpose of review: Antipsychotics are frequently prescribed to women of childbearing age and are increasingly prescribed during pregnancy. A small, but growing, body of research on implications for pregnancy and infant outcomes is available to inform the risks and benefits of in utero exposure to antipsychotics. This review examines the existing published research on the use of common typical and atypical antipsychotics in pregnancy and the implications for pregnancy and infant outcomes. Recent findings: The majority of studies do not show associations with major malformations and antipsychotic use in pregnancy, with the possible exception of risperidone. There is concern that atypical antipsychotics may be associated with gestational diabetes. Metabolic changes during pregnancy may necessitate dose adjustments. Summary: In general, it is recommended that women who need to take an antipsychotic during pregnancy continue the antipsychotic that has been most effective for symptom remission. Further study on risperidone is needed to better understand its association with malformations, and it is not considered a first-line agent for use during pregnancy. © 2019, Springer Nature Switzerland AG.
引用
收藏
页码:17 / 31
页数:14
相关论文
共 80 条
[1]  
Alexander G.C., Gallagher S.A., Mascola A., Moloney R.M., Stafford R.S., Increasing off-label use of antipsychotic medications in the United States, 1995-2008, Pharmacoepidemiol Drug Saf, 20, 2, pp. 177-184, (2011)
[2]  
Camsari U., Viguera A.C., Ralston L., Baldessarini R.J., Cohen L.S., Prevalence of atypical antipsychotic use in psychiatric outpatients: comparison of women of childbearing age with men, Arch Womens Ment Health, 17, 6, pp. 583-586, (2014)
[3]  
Olfson M., King M., Schoenbaum M., Antipsychotic treatment of adults in the United States, J Clin Psychiatry, 76, 10, pp. 1346-1353, (2015)
[4]  
Toh S., Li Q., Cheetham T.C., Cooper W.O., Davis R.L., Dublin S., Hammad T.A., Li D.K., Pawloski P.A., Pinheiro S.P., Raebel M.A., Scott P.E., Smith D.H., Bobo W.V., Lawrence J.M., Dashevsky I., Haffenreffer K., Avalos L.A., Andrade S.E., Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries, Arch Womens Ment Health, 16, 2, pp. 149-157, (2013)
[5]  
Park Y., Huybrechts K.F., Cohen J.M., Bateman B.T., Desai R.J., Patorno E., Mogun H., Cohen L.S., Hernandez-Diaz S., Antipsychotic medication use among publicly insured pregnant women in the United States, Psychiatr Serv, 68, 11, pp. 1112-1119, (2017)
[6]  
Gilbert P.L., Harris M.J., McAdams L.A., Jeste D.V., Neuroleptic withdrawal in schizophrenic patients: a review of the literature, Arch Gen Psychiatry, 52, 3, pp. 173-188, (1995)
[7]  
Viguera A.C., Whitfield T., Baldessarini R.J., Newport D.J., Stowe Z., Reminick A., Et al., Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation, Am J Psychiatr, 164, pp. 1817-1824, (2007)
[8]  
Jablensky A.V., Morgan V., Zubrick S.R., Bower C., Yellachich L.-A., Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders, Am J Psychiatr, 162, 1, pp. 79-91, (2005)
[9]  
Diego M.A., Field T., Hernandez-Reif M., Schanberg S., Kuhn C., Gonzalez-Quintero V.H., Prenatal depression restricts fetal growth, Early Hum Dev, 85, 1, pp. 65-70, (2009)
[10]  
Field T., Diego M., Hernandez-Reif M., Prenatal depression effects on the fetus and newborn: a review, Infant Behav Dev, 29, 3, pp. 445-455, (2006)